Department of Medicine, Director of Outpatient Hepatology, Division of Liver Diseases, Mount Sinai School of Medicine, Annenberg 21-42, New York, NY 10029, USA.
Expert Rev Gastroenterol Hepatol. 2009 Dec;3(6):693-9. doi: 10.1586/egh.09.64.
Hepatitis B virus (HBV) infection is an important health problem and a major cause of chronic hepatitis that can lead to cirrhosis and hepatocellular carcinoma. Durable viral suppression has been documented to lower the risk of hepatocellular carcinoma and disease progression. Treatment of chronic HBV infection remains a major clinical challenge because long-term use with approved oral antiviral agents is associated with drug resistance. Antiviral resistance can result in poor clinical outcomes; therefore first-line therapy with the most potent agent(s) is recommended to lower the risk. Early detection of resistance is paramount to possibly reduce the risk of liver-related morbidity and mortality. It is important that clinicians monitor for therapeutic efficacy and resistance, so as to optimize the management of chronic HBV.
乙型肝炎病毒 (HBV) 感染是一个重要的健康问题，也是导致慢性肝炎的主要原因，慢性肝炎可进一步发展为肝硬化和肝癌。大量研究证实，持久抑制病毒可降低肝癌和疾病进展风险。慢性 HBV 感染的治疗仍然是一个重大的临床挑战，因为长期使用已批准的口服抗病毒药物会产生耐药性。抗病毒耐药会导致不良临床结局，因此推荐使用最有效的药物进行一线治疗，以降低耐药风险。早期检测耐药至关重要，这可能会降低肝相关发病率和死亡率。临床医生监测治疗效果和耐药性非常重要，这有助于优化慢性 HBV 的管理。
